From professional translators, enterprises, web pages and freely available translation repositories.
reperfusion arrhythmias may lead to cardiac arrest, can be life threatening and may require the use of conventional antiarrhythmic therapies.
l- arritmiji ta’ riperfużjoni jistgħu jwasslu għal arrest kardijaku, jistgħu jkunu ta’ periklu għall-ħajja u għandhom mnejn ikollhom bżonn terapiji antiarritmiċi konvenzjonali.
treatment of st segment elevation myocardial infarction (stemi) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.
trattament ta’ infart mijokardijaku b’elevazzjoni tas-segment st (stemi) f’pazjenti li qed jirċievu trattament b’trombolitiċi jew f’dawk li inizjalment m’għandhomx jirċievu l-ebda forma oħra ta’ terapija ta’ riperfużjoni.
uncommon (may affect up to 1 in 100 people): irregular heart beat (reperfusion arrhythmias), sometimes leading to cardiac arrest.
mhux komuni (jistgħu jaffettwaw sa 1 minn kull 100 persuna): taħbit irregolari tal-qalb (arritmiji ta’ riperfużjoni), li kultant jistgħu jikkaġunaw arrest kardijaku.
in the predefined stratum comparing fondaparinux to ufh (patients treated with primary pci (58.5%), fibrin-specific lytics (13%), non-fibrin-specific lytics (2.6%) and no reperfusion (25.9%), the effects of fondaparinux and ufh on the incidence of death/re-mi at day 30 were not statistically different: respectively, 8.3% vs 8.7% (hazard ratio 0.94, 95% ci, 0.79, 1.11 p = 0.460).
fl-istratum definit minn qabel li kkumpara fondaparinux ma’ ufh (pazjenti trattati b’pci primarja (58.5%), sustanzi litiċi speċifiċi għal-fibrin (13%), sustanzi litiċi li mhumiex speċifiċi għal-fibrin (2.6%) u ebda reperfużjoni (25.9%), l-effetti ta’ fondaparinux u ufh fuq l-inċidenza ta’ mewt/re-mi f’jum 30 ma kienux statistikament differenti: rispettivament, 8.3% vs 8.7% (hazard ratio 0.94, 95% ci, 0.79, 1.11 p = 0.460).